Isis Pharmaceuticals Inc. (ISIS: Quote) and Genzyme announced after the bell Tuesday that they received FDA approval for KYNAMROTM injection, to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol in patients with homozygous familial hypercholesterolemia.Isis Pharmaceuticals gapped up sharply Wednesday and has continued to rise in early trade. The stock is now up 1.72 at $15.10 on above average volume and has broken out to a 4-month high.
Click here to receive FREE breaking news email alerts for ISIS Pharmaceuticals Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News